Immatics (IMTX) Income from Continuing Operations (2019 - 2025)

Immatics' (IMTX) quarterly Income from Continuing Operations came in at 46184590.49 in Q4 2025, down 228.9% year-on-year from 35831072.36 in Q4 2024, and up 22.23% quarter-over-quarter from 59386829.59 in Q3 2025.

Immatics (IMTX) Income from Continuing Operations (2019 - 2025) Analysis & Trends

Immatics has disclosed Income from Continuing Operations across 7 years of filings, most recently posting 46184590.49 for Q4 2025.

  • Income from Continuing Operations for Q4 2025 came in at 46184590.49, down 228.9% year-over-year; the trailing twelve-month figure through Dec 2025 was 229391557.84 (down 1631.15% YoY), and the FY2025 annual result was 226442407.73, down 1492.47% from the prior year.
  • Income from Continuing Operations came in at 46184590.49 for Q4 2025 at Immatics, up from 59386829.59 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 96141693.63 in Q1 2022 to a low of 81897283.43 in Q2 2025.
  • The 5-year median for Income from Continuing Operations is 23996855.1 (2023), against an average of 18209114.54.
  • Across the five-year window, Income from Continuing Operations jumped 449.38% in 2022 and plunged 9127.64% in 2025, its largest moves.
  • Immatics' Income from Continuing Operations stood at 19203840.36 in 2021, then soared by 111.78% to 2261888.41 in 2022, then tumbled by 1343.81% to 28133676.74 in 2023, then jumped by 227.36% to 35831072.36 in 2024, then slumped by 228.9% to 46184590.49 in 2025.
  • The last three Income from Continuing Operations figures came in at 46184590.49 (Q4 2025), 59386829.59 (Q3 2025), and 81897283.43 (Q2 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -2.97 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 30.80 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -3.40 Mn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -14.46 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.96 Bn 91.96 Bn - -56.48 Mn
10 Immatics 14.67 Bn 14.67 Bn - -46.18 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -46.18 Mn
Sep 30, 2025 -59.39 Mn
Jun 30, 2025 -81.90 Mn
Mar 31, 2025 -41.92 Mn
Dec 31, 2024 35.83 Mn
Sep 30, 2024 657,833.48
Jun 30, 2024 -19.07 Mn
Mar 31, 2024 -2.43 Mn
Dec 31, 2023 -28.13 Mn
Sep 30, 2023 -28.84 Mn
Jun 30, 2023 -26.80 Mn
Mar 31, 2023 -21.20 Mn
Dec 31, 2022 2.26 Mn
Sep 30, 2022 -19.98 Mn
Jun 30, 2022 -12.47 Mn
Mar 31, 2022 96.14 Mn
Dec 31, 2021 -19.20 Mn
Sep 30, 2021 -32.08 Mn
Jun 30, 2021 -31.95 Mn
Mar 31, 2021 -27.52 Mn